Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 10/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078759 | 0.92 | ACE (0.61) | KLK5ACEF2PRSS1CMA1 | |
| SCHEMBL6078614 | 0.92 | ACE (0.61) | KLK5ACEF2PRSS1CMA1 | |
| SCHEMBL12658455 | 0.87 | KLK5 (0.69) | KLK5ACEF2PRSS1CMA1 | |
| SCHEMBL28002552 | 0.87 | KLK5 (0.69) | KLK5ACEF2PRSS1CMA1 | |
| SCHEMBL28002546 | 0.87 | KLK5 (0.69) | KLK5ACEF2PRSS1CMA1 | |
| SCHEMBL7268512 | 0.87 | KLK5 (0.69) | KLK5ACEF2PRSS1CMA1 | |
| SCHEMBL24447150 | 0.83 | F2 (0.56) | ACEF2PRSS1CMA1 | |
| SCHEMBL16706511 | 0.83 | F2 (0.56) | ACEF2PRSS1CMA1 | |
| SCHEMBL28394567 | 0.83 | F2 (0.56) | ACEF2PRSS1CMA1 | |
| SCHEMBL30192889 | 0.83 | KLK5 (0.52) | KLK5ACEF2PRSS1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | KLK5 520/4885ACE 387/4885NPC1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.